First In Class Small Peptides Targeting Kindlin-1

Our technology is a small peptide targeting EGFR/RAS-driven cancers by inhibiting Kindlin-1, a critical regulator of integrin signaling in cancer progression. Kindlin-1 overexpression correlates with poor patient survival in various cancers. This therapy disrupt Kindlin-1 binding to β1-integrin, selectively inhibiting EGFR/RAS-dependent cancer cell viability without affecting other cells. Demonstrations in vitro and in vivo across multiple cancer types validate its specificity and efficacy, paving the way for a novel therapeutic approach.